Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: Role of RAGE-NFκB and Nrf2-antioxidant signaling pathways

Journal of Neurochemistry

Volumn 133, Issue 5, 2015, Pages 700-707

  Abdelsalam, Rania M ^a   Safar, Marwa M ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

apoptosis; dipeptidyl peptidase 4; neuroinflammation; RAGE; rotenone; Vildagliptin

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; VILDAGLIPTIN; ADAMANTANE; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; ANTIDIABETIC AGENT; ANTIOXIDANT; DOPAMINE; IMMUNOGLOBULIN RECEPTOR; NEUROPROTECTIVE AGENT; NFE2L2 PROTEIN, RAT; NITRILE; PYRROLIDINE DERIVATIVE; ROTENONE; UNCOUPLING PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; MALE; MOTOR PERFORMANCE; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; STRIATE CORTEX; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; PARKINSON DISEASE, SECONDARY; WISTAR RAT;

RATTUS;

ADAMANTANE; ANIMALS; ANTIOXIDANTS; APOPTOSIS; DOPAMINE; HYPOGLYCEMIC AGENTS; MALE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; NF-KAPPA B; NITRILES; OXIDATIVE STRESS; PARKINSON DISEASE, SECONDARY; PYRROLIDINES; RATS; RATS, WISTAR; RECEPTORS, IMMUNOLOGIC; ROTENONE; SIGNAL TRANSDUCTION; UNCOUPLING AGENTS;

EID: 84928009282     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13087     Document Type: Article

References (62)

1. Akarte A. S., Srinivasan B. P., and, Gandhi S., (2012) Relationships between the islets blood flow, nitric oxide, insulin, and cytosolic calcium in rat pancreatic islets: effects of DPP-IV inhibitor vildagliptin. Eur. J. Pharm. Sci. 45, 546-551.
2. Barneoud P., Mazadier M., Miquet J. M., Parmentier S., Dubedat P., Doble A., and, Boireau A., (1996) Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. Neuroscience 74, 971-983.
3. Berman S. B., and, Hastings T. G., (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 73, 1127-1137.
4. Bertilsson G., Patrone C., Zachrisson O., et al,. (2008) Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J. Neurosci. Res. 86, 326-338.
5. Bianchi R., Giambanco I., and, Donato R., (2010) S100B/RAGE-dependent activation of microglia via NF-kappaB and AP-1 Co-regulation of COX-2 expression by S100B, IL-1beta and TNF-alpha. Neurobiol. Aging 31, 665-677.
6. van den Buuse M., and, de Jong W., (1989) Differential effects of dopaminergic drugs on open-field behavior of spontaneously hypertensive rats and normotensive Wistar-Kyoto rats. J. Pharmacol. Exp. Ther. 248, 1189-1196.
7. Chung T. W., Choi H. J., Kim C. H., Jeong H. S., and, Ha K. T., (2013) Lipocalin-2 elicited by advanced glycation end-products promotes the migration of vascular smooth muscle cells. Biochim. Biophys. Acta 1833, 3386-3395.
8. Dauer W., and, Przedborski S., (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889-909.
9. Dhindsa S., and, Jialal I., (2014) Potential anti-atherosclerotic effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus. Curr. Diab. Rep. 14, 463.
10. Eftekharzadeh B., Maghsoudi N., and, Khodagholi F., (2010) Stabilization of transcription factor Nrf2 by tBHQ prevents oxidative stress-induced amyloid beta formation in NT2N neurons. Biochimie 92, 245-253.
11. Gao F., Chen D., Hu Q., and, Wang G., (2013) Rotenone directly induces BV2 cell activation via the p38 MAPK pathway. PLoS ONE 8, e72046.
12. Gorrell M. D., (2005) Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin. Sci. (Lond.) 108, 277-292.
13. Hamamoto S., Kanda Y., Shimoda M., Tatsumi F., Kohara K., Tawaramoto K., Hashiramoto M., and, Kaku K., (2013) Vildagliptin preserves the mass and function of pancreatic beta cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetes Obes. Metab. 15, 153-163.
14. Harkavyi A., Abuirmeileh A., Lever R., Kingsbury A. E., Biggs C. S., and, Whitton P. S., (2008) Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J. Neuroinflammation 5, 19.
15. Hecker M., Cattaruzza M., and, Wagner A. H., (1999) Regulation of inducible nitric oxide synthase gene expression in vascular smooth muscle cells. Gen. Pharmacol. 32, 9-16.
16. Hernandez-Romero M. C., Delgado-Cortes M. J., Sarmiento M., et al,. (2012) Peripheral inflammation increases the deleterious effect of CNS inflammation on the nigrostriatal dopaminergic system. Neurotoxicology 33, 347-360.
17. Herrera A. J., Tomas-Camardiel M., Venero J. L., Cano J., and, Machado A., (2005) Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons. J. Neural. Transm. 112, 111-119.
18. Itou M., Kawaguchi T., Taniguchi E., and, Sata M., (2013) Dipeptidyl peptidase-4: a key player in chronic liver disease. World J. Gastroenterol. 19, 2298-2306.
19. Jungraithmayr W., De Meester I., Matheeussen V., Inci I., Augustyns K., Scharpe S., Weder W., and, Korom S., (2010) Inhibition of CD26/DPP IV attenuates ischemia/reperfusion injury in orthotopic mouse lung transplants: the pivotal role of vasoactive intestinal peptide. Peptides 31, 585-591.
20. Kanninen K., White A. R., Koistinaho J., and, Malm T., (2011) Targeting Glycogen Synthase Kinase-3beta for Therapeutic Benefit against Oxidative Stress in Alzheimer's Disease: Involvement of the Nrf2-ARE Pathway. Int. J. Alzheimers. Dis. 2011, 985085.
21. Keeney P. M., Xie J., Capaldi R. A., and, Bennett J. P., Jr, (2006) Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci. 26, 5256-5264.
22. Khurana N., and, Gajbhiye A., (2013) Ameliorative effect of Sida cordifolia in rotenone induced oxidative stress model of Parkinson's disease. Neurotoxicology 39, 57-64.
23. Kim S., Moon M., and, Park S., (2009) Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J. Endocrinol. 202, 431-439.
24. Kosaraju J., Murthy V., Khatwal R. B., Dubala A., Chinni S., Muthureddy Nataraj S. K., and, Basavan D., (2013) Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease. J. Pharm. Pharmacol. 65, 1773-1784.
25. Lander H. M., Tauras J. M., Ogiste J. S., Hori O., Moss R. A., and, Schmidt A. M., (1997) Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 272, 17810-17814.
26. Li J., and, Schmidt A. M., (1997) Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J. Biol. Chem. 272, 16498-16506.
27. Li Y., Perry T., Kindy M. S., et al,. (2009) GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl Acad. Sci. USA 106, 1285-1290.
28. Lin T. K., Cheng C. H., Chen S. D., Liou C. W., Huang C. R., and, Chuang Y. C., (2012) Mitochondrial Dysfunction and Oxidative Stress Promote Apoptotic Cell Death in the Striatum via Cytochrome c/Caspase-3 Signaling Cascade Following Chronic Rotenone Intoxication in Rats. Int. J. Mol. Sci. 13, 8722-8739.
29. Love S., (1999) Oxidative stress in brain ischemia. Brain Pathol. 9, 119-131.
30. MacKenzie E. L., Ray P. D., and, Tsuji Y., (2008) Role and regulation of ferritin H in rotenone-mediated mitochondrial oxidative stress. Free Radic. Biol. Med. 44, 1762-1771.
31. Maeda S., Matsui T., and, Yamagishi S., (2012) Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats. Int. J. Cardiol. 158, 171-173.
32. Maeda S., Yamagishi S., Matsui T., Nakashima S., Ojima A., Maeda S., Nishino Y., Ishibashi Y., Yoshida Y., and, Yamakawa R., (2013) Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats. Ophthalmic Res. 50, 221-226.
33. Mahali S., Raviprakash N., Raghavendra P. B., and, Manna S. K., (2011) Advanced glycation end products (AGEs) induce apoptosis via a novel pathway: involvement of Ca2 + mediated by interleukin-8 protein. J. Biol. Chem. 286, 34903-34913.
34. Matsui T., Nishino Y., Takeuchi M., and, Yamagishi S., (2011) Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol. Res. 63, 383-388.
35. Merchenthaler I., Lane M., and, Shughrue P., (1999) Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 403, 261-280.
36. Moore D. J., West A. B., Dawson V. L., and, Dawson T. M., (2005) Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28, 57-87.
37. Munch G., Westcott B., Menini T., and, Gugliucci A., (2012) Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino Acids 42, 1221-1236.
38. Numazawa S., Ishikawa M., Yoshida A., Tanaka S., and, Yoshida T., (2003) Atypical protein kinase C mediates activation of NF-E2-related factor 2 in response to oxidative stress. Am. J. Physiol. Cell Physiol. 285, C334-C342.
39. Pan C., and, Wang X., (2013) Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability. Ther. Clin. Risk Manag. 9, 247-257.
40. Perkins N. D., (2007) Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol. 8, 49-62.
41. Pintana H., Apaijai N., Chattipakorn N., and, Chattipakorn S. C., (2013) DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. J. Endocrinol. 218, 1-11.
42. Pipatpiboon N., Pintana H., Pratchayasakul W., Chattipakorn N., and, Chattipakorn S. C., (2013) DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption. Eur. J. Neurosci. 37, 839-849.
43. Ramasamy R., Yan S. F., and, Schmidt A. M., (2009) RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts. J. Leukoc. Biol. 86, 505-512.
44. Rohnert P., Schmidt W., Emmerlich P., et al,. (2012) Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia. J. Neuroinflammation 9, 44.
45. Sathe K., Maetzler W., Lang J. D., et al,. (2012) S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-alpha pathway. Brain 135 (Pt 11), 3336-3347.
46. Sato K., Nakamura A., Shirakawa J., Muraoka T., Togashi Y., Shinoda K., Orime K., Kubota N., Kadowaki T., and, Terauchi Y., (2012) Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance and beta-cell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet. Endocrinology 153, 1093-1102.
47. Schapira A. H., Cooper J. M., Dexter D., Clark J. B., Jenner P., and, Marsden C. D., (1990) Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54, 823-827.
48. Sedo A., and, Malik R., (2001) Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochim. Biophys. Acta 1550, 107-116.
49. Surh Y. J., and, Na H. K., (2008) NF-kappaB and Nrf2 as prime molecular targets for chemoprevention and cytoprotection with anti-inflammatory and antioxidant phytochemicals. Genes Nutr. 2, 313-317.
50. Teismann P., Tieu K., Cohen O., Choi D. K., Wu D. C., Marks D., Vila M., Jackson-Lewis V., and, Przedborski S., (2003) Pathogenic role of glial cells in Parkinson's disease. Mov. Disord. 18, 121-129.
51. Teismann P., Sathe K., Bierhaus A., Leng L., Martin H. L., Bucala R., Weigle B., Nawroth P. P., and, Schulz J. B., (2012) Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity. Neurobiol. Aging 33, 2478-2490.
52. Thakur P., and, Nehru B., (2014) Modulatory effects of sodium salicylate on the factors affecting protein aggregation during rotenone induced Parkinson's disease pathology. Neurochem. Int. 75C, 1-10.
53. Thakur P., and, Nehru B., (2015). Inhibition of neuroinflammation and mitochondrial dysfunctions by carbenoxolone in the rotenone model of Parkinson's disease. Mol. Neurobiol. 51, 209-219.
54. Thiffault C., Langston J. W., and, Di Monte D. A., (2000) Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Res. 885, 283-288.
55. Vallance P., and, Leiper J., (2002) Blocking NO synthesis: how, where and why? Nat. Rev. Drug. Discov. 1, 939-950.
56. Vaz S. M., and, Augusto O., (2008) Inhibition of myeloperoxidase-mediated protein nitration by tempol: Kinetics, mechanism, and implications. Proc. Natl Acad. Sci. USA 105, 8191-8196.
57. Weiss S. J., (1986) Oxygen, ischemia and inflammation. Acta Physiol. Scand. Suppl. 548, 9-37.
58. Wilms H., Zecca L., Rosenstiel P., Sievers J., Deuschl G., and, Lucius R., (2007) Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications. Curr. Pharm. Des. 13, 1925-1928.
59. Xie J., Mendez J. D., Mendez-Valenzuela V., and, Aguilar-Hernandez M. M., (2013) Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell. Signal. 25, 2185-2197.
60. Xu Y., Liu C., Chen S., et al,. (2014) Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson's disease. Cell. Signal. 26, 1680-1689.
61. Yao D., and, Brownlee M., (2010) Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 59, 249-255.
62. del Zoppo G., Ginis I., Hallenbeck J. M., Iadecola C., Wang X., and, Feuerstein G. Z., (2000) Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol. 10, 95-112.